METHODS AND COMPOSITIONS FOR TREATING CHRONIC LUNG DISEASES
The present invention provides, among other things, methods and compositions for treating Chronic Lung Disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof.
1 . A method of treating Chronic Lung Disease comprising administering to a subject in need of treatment insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof.
2 . The method of claim 1 , wherein the IGF-I or agonist or analog thereof comprises IGF-1 and an IGF binding protein.
3 . The method of claim 2 , wherein the IGF-I or agonist or analog thereof comprises IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3).
4 . The method of any one of the preceding claims claim 1 , wherein the subject in need of treatment is an infant.
5 - 6 . (canceled)
7 . The method of claim 1 , wherein the IGF-I or agonist or analog thereof is administered subcutaneously, intravenously, intramuscularly, or orally.
8 . (canceled)
9 . The method of claim 1 , wherein the IGF-I or agonist or analog thereof is administered at a dosage of about 100 to 500 micrograms/kg/24 hours.
10 - 11 . (canceled)
12 . The method of claim 1 , wherein the IGF-I or agonist or analog thereof is administered from the time of birth up to post-menstrual age (PMA) of about 24-34 weeks.
13 . The method of claim 1 , wherein the IGF-I or agonist or analog thereof is administered from the time of birth up to PMA of about 28 to 32 weeks.
14 . The method of claim 1 , wherein the IGF-I or agonist or analog thereof is administered from the time of birth up to PMA of about 29 weeks plus 6 days.
15 . The method of claim 1 , wherein the subject has reduced IGF-1 serum levels.
16 . The method of claim 15 , wherein the reduced IGF-1 serum levels are about 30 to 50 micrograms/L.
17 . The method of claim 1 , wherein the IGF -1 is recombinantly produced.
18 . The method of claim 3 , wherein the IGFB P-3 is recombinantly produced.
19 . The method of claim 3 , wherein the IGF-1 and the IGFBP-3 are complexed prior to administration to the subject.
20 . The method of claim 3 , wherein the IGF-1 and IGFBP-3 are complexed in equimolar amounts.
21 . The method of claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of Chronic Respiratory Morbidity (CRM) through 12 months corrected age (CA).
22 . The method of claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of Bronchopulmonary dysplasia (BPD) through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months.
23 . The method of claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of Severe Intraventricular Hemorrhage (IVH) Grade III or IV through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months.
24 . The method of claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of retinopathy of prematurity (ROP) through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months.
25 . The method of claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in increased Functional Status as Assessed by PREMature Infant Index (PREMII) through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months.